EPIDEMIOLOGY OF HEART FAILURE:
Heart failure rates, mortality, prevalence, and incidence have been classified by several different research studies, each with variances in the populations studied and data collection methods. For example, the Framingham study -which began in 1948 -had a list of symptoms, physical findings, and physiological measurements used to classifY congestive heart failure; classification as a case required multiple criteria be met, with no other medical explanation than heart failure for the presence of "minor" criteria. 17 In contrast, the development of ACCFIAHA guidelines re-defined HF as a clinical syndrome characterized by symptoms in the medical history of an individual as well as signs in a physical examination. With no single diagnostic test for presence of HF, most diagnoses are subjective and based on qualitative judgment. Interpretation of epidemiological data of HF is compromised by these variances. Because there is not a universal classification for heart failure, this limitation should be borne in mind when considering the following data presented.
The National Health and Nutrition Examination Survey (NHANES) is a program of studies designed to assess the health and nutritional status of adults and children in the US and is a combination of both physical examinations of interviews. 6 Results of the NHANES 2005-2008 estimated that 5.7 million Americans over the age of 20 years have HF. 26Projections on crude prevalence from 2010 show that approximately 6.6 million Americans (2.8% of the popUlation) had HF, with the trend increasing each year. It's estimated that by 2030, with trends continuing upward, an additional 3 million people will have HF, a 25% increase in prevalence from 2010. 27 Annual rates per 1000 population of new HF events for white men are as much as 15.2 for those 65 to 74 years, 31.7 for those 75 to 84, and 65.2 for those greater than 85 years; for white women in the same age groups, rates are 8. 2, 19.8, and 45.6 . For black men, rates are 16.9,25.5, and 50.6, and for black women, rates are 14.2, 25.5, and 44.0. (CHS, NHLBI)
The Multi-Ethnic Study of Atherosclerosis (MESA) was a medical research study on cardiovascular disease risk factors that involved more than 6,000 men and women from six communities in the US and was funded by the NHLBI and NIH. Data from MESA ranked the risk of developing HF by all ethnic groups in the following order:
African American, Hispanic, white, and Chinese American (4.6,3.5,2.4, and 1.0 per 1000 person-years, respectively). 27 These differences in risk can be directly correlated with prevalence of hypertension and other comorbid conditions, as well as socioeconomic status (SES). African Americans also had the highest proportion of incident HF not proceeded by clinical myocardial infarction (MI) 27 In the ARIC study, age adjusted incidence of HF per 1000 person-years was 9.1 for black men (BM), 8.1 for black females (BF), 6.0 for white men (WM), and 3.4 for white females (WF). The 30-day, 1
year, and 5 year case fatality rates after rehospitalization for HF were 42.3% in BM, 22% in BF, and 10.4% in WM. 19 Similarly, the CARDIA study, looking at CVD differences in young black and white adults, concluded that HF before the age of 50 years was more common among black individuals. Hypertension, obesity, and systolic dysfunction were all considered important risk factors in the development of disease and targets for . 27 preventIOn.
Risk factor epidemiology for HF patients shows a distinct group of lifestyle conditions that critically affect the severity of disease onset and progression. The
Framingham study listed lifestyle-related factors increasing risk of HF including cholesterol concentration, smoking status, blood pressure, and diabetes; presence of left ventricular hypertrophy (LV H) as a consequence of hypertension -resulting in an enlargement of the left ventricle -as determined by electrocardiography (ECG) is also considered a significant risk factor. 17 Older males and females had a higher relative risk for the development ofHF with the presence of hypertension, diabetes, and LVH: 1.9, 2.0, and 4.9, respectively, in males, and 1.9,3.6, and 5.4 in females. Men aged 35-64 also had a significantly increased risk of HF development if they were smokers (RR=1.5).17
Among 20,900 male physicians in the Physicians Health Study, the lifetime risk ofHF was higher in men with hypertension; healthy lifestyle factors (normal weight, not smoking, regular exercise, moderate alcohol intake, etc) were related to lower risk of HF. 27 Among the participants of the Health Aging, Body and Composition (ABC) study, there was a higher proportion of HF attributable to modifiable risk factors in black participants over white participants (67.8% vs. 48.9%); in this study, inflammatory markers were also attributed to HF risk .27 In 2008, overall death rate for HF was 84.6 per 100,000 individuals; the rates listed by varying race/sex class were listed as 98.9 for WM, 102.7 for BM, 75.9 for WF, and 78.8 BF. (NCHS, NHLBI) Any-mention mortality with HF was 281, 437 (124,598 males and 156,839 females) with HF as the major underlying cause in 56,830 ofthose deaths in 2008. Additionally, 1 in 9 deaths had HF listed on the death certificate. 27
Survival after HF diagnosis has improved over time, as shown by data in the Framingham Heart Study (FHS) and the Olmsted County study. However, death rate remains highapproximately 50% of people diagnosed with HF will die within an average of 5 years. 27
A unique aspect of HF mortality is the proportion of deaths that are sudden. The FHS predicted that between 40-50% of deaths in the presence of HF were sudden, defined as occurring within one hour in a previously stable patient. 17 When looking at 30 year follow up in the Framingham population, the presence of previous HF increased the risk of sudden death as much as sevenfold when CHD was absent and nine-fold in the presence of CHD.17
Data from Kaiser Permanente suggest that survival after the onset of HF has improved in elderly populations, although mortality rates are still high.2 For women ages 65-74, 15 year mortality rates were approximately 60%; the corresponding rate of men in the same age group was even higher. 17 This improvement seen over time can be attributed to advancements in surgical and treatment approaches in HF management 17 .
The one area in which rates do not improve for heart failure patients lies in the hospitalization and rehospitalization data. From 1999 to 2009, hospital discharges for HF were virtually unchanged, with first-listed discharges of975,000 and 1,094,000 respectively. (NHDS 2009, NCHS, NHLBI)Despite the insignificant change in discharge rates, rate of hospitalization for HF has increased more than threefold over the past three decades, with the increasing pattern largely being attributed to elderly populations. One age group where a positive trend is also witnessed is in the 45-64 year age group.17 With this said, the overall case-fatality rate has substantially declined by more than 50% through the 1980's and 1990's.17
The amount of heart failure treatment paints an even larger picture of the overall burden of the disease, with HF imposing a large economic burden on the health care system. In developed countries, the cost of HF care constitutes approximately 1 % to 2% of overall health care spending. 9 In 2009, the estimated direct and indirect cost of treating HF patients in the United States was more than $37 billion, this being the largest consumer of Medicare spending above any other diagnosis. 4 Alarmingly, this figure may increase in following years due to the aging population and increased survival after primary hospitalization. Elderly patients, often covered by Medicare, are rehospitalized more frequently than younger HF patients -25% being rehospitalized in the first 30 days;
Medicare, however, does not reimburse hospitals for this time period shifting the cost burden to the healthcare facility.
In a study looking at the lifetime medical costs ofHF patients in Olmsted County, Minnesota, 1054 patients were randomly sampled and assessed for total accrued debts 9 . Total costs for the cohort during the study period (1987 to 2006) were estimated at $100, 967,086 in 2006, combining both inpatient and outpatient costs. 9 The majority of costs were due to hospitalizations (77%) with an average cost of $73,762 per person. The highest proportion of inpatient costs were rooming, procedures, and evaluation and management. Total outpatient costs accounted for over $22 million, with an average cost of$22,032 per person. 9 The highest proportion of outpatient cost was due to evaluation and management and procedures. Among evaluation and management, office visits comprised the largest amount of cost. Dialysis, if needed, was the largest proportion of procedural cost. Lifetime costs were estimated for all patients at approximately $109,541 per person, with comorbid conditions such as diabetes increasing estimated costs over 30%.9
Although overall trends are decreasing for incidence of HF, the cost burden associated with the management of heart disease is highly significant. In 2009, the US spent $2.6 trillion on health care, representing more than 17.6% of our gross domestic product. 9 Although annual costs of caring for the populations affected by HF in the US are estimated as being high, little is known about the cumulative costs of caring for HF patients after diagnosis. Some estimates suggest that over 50% of the total costs were accumulated within the last 6 months of the individual's life. 9 Identifying patient factors associated with higher costs may be helpful in targeting those patients for cost-saving interventions. Additionally, standardizing treatment practices among physicians and medical institutions may improve patient outcomes and reduce the total cost associated with this disease.
PATHOPHYSIOLOGY/ETIOLOGY OF HEART FAILURE:
Heart failure (HF) is a chronic, progressive condition in which the heart muscle is unable to pump enough blood to meet the body's needs for oxygen and nutrients. I In order to compensate for this reduction in blood flow and increase in demand from surrounding body tissue, the heart will typically undergo one of the following: enlargement, increase in muscle mass, or increased pumping action. The body in addition will compensate in other ways: blood vessels can narrow to maintain blood pressure (making up for the reduction in pumping action/power), or divert blood from less important tissues and organs to maintain flow to the vital organs (i.e. the heart and brain).l While these temporary solutions can delay the outcome of total heart failure, conditions will worsen until these substitute process no longer work, or some type of medical intervention occurs. Once an individual's body compensation cannot keep up with the energy demands it he/she will experience fatigue, breathing problems, or any myriad of life threatening symptoms --the most severe being death.
HF primarily reflects the impairment of the pumping function of the heart's left ventricle, although other etiologies exist. 17 The result of this impairment is a reduction in blood flow from the left ventricle to the aorta, which in tum reduces peripheral arterial blood flow. In LV failure, the left side of the heart must exert a larger amount of energy to pump a normal amount of blood. This increase in exertion often leads to a hardening of the left ventricular wall ("stiffness") or enlargement of the ventricle (left-ventricular hypertrophy). Additionally, failure to eject blood from the left ventricle leads to an increased back pressure in the pulmonary circulation, accompanying and exacerbating respiratory dysfunction. Heart failure can occur on either the left or right side, with each classification having distinguishing impairments. Mechanisms of left heart failure include "systolic" and "diastolic" dysfunction. Systolic dysfunction describes a heart with diminished ejection fraction, where the left ventricle expels a reduced amount of blood at each contraction of the myocardium; diastolic dysfunction describes an incomplete relaxation of the left ventricle (typically due to stiffness of the ventricular wall), resulting in a reduced volume of blood entering the chamber during each relaxation. 17 The heart moves deoxygenated blood that returns to the heart through the veins through the right atrium into the right ventricle. The ventricle then pumps blood back out of the heart into the lungs to be replenished with oxygen. Right-sided heart failure occurs due to an impainnent of right-ventricular (RV) function, and occurs as a result ofleftsided, LV failure. 1 Increased fluid pressure in the lungs, which often times occurs due to left-sided failure, damages the right ventricular tissue. When the right side loses power, blood backs up in the body's veins, typically resulting in peripheral edema in the legs and ankles; right failure also occurs in conjunction with obesity or sleep-disordered b
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A myriad of conditions can damage or weaken the heart and cause heart failure.
The most common fonn of heart disease and the a leading cause of HF is coronary artery disease (CAD)?O CAD is one of several tenns referring to atherosclerosis, or narrowing of the arteries that supply blood to the heart due to a build-up of fatty deposits. This slowing of blood flow through the body leaves areas of the myocardium weak and oxygen deprived. In most cases, however, the reduction in blood flow is not enough to fully impair the heart muscle, but sufficiently weaken cardiac output; if plaque build-up occludes the arteries to the point in which myocardial cells are deprived of blood flow (ischemia), weakening or death of cell tissue occurs. When these plaques rupture, blood clots block blood flow to an area of the heart muscle, weakening the heart's pumping b 'l' 20 a 1 lty.
Other contributing factors to heart failure include hypertension, heart valve dysfunction, cardiomyopathy, myocarditis, congenital heart defects, heart arrhythmias, and other diseases. Hypertension, one of the most common chronic conditions related to vascular health (affecting more than 70 million Americans), is a critical measure of circulatory function. 17 It reflects a balance between the blood volume ejected from the left ventricle of the heart during each contraction and the arterial resistance to blood flow.
Several physiologic mechanisms operate to simultaneously maintain blood pressure based on the perfusion needs of surrounding body tissues. Hypertension, however, causes the heart to work harder than normal to pump blood throughout the body, which leads to thickening of the myocardium to compensate for the extra work it must perform. Over time, the cardiac muscle becomes either too stiff or too weak to effectively pump blood?O Valve damage, typically due to a heart defect, CAD, or infections, forces the heart to overexert to keep blood flowing in the normal direction. Myocarditis, an inflammation of the heart muscle (commonly caused by infection) can also lead to left-sided failure.
Congenital heart defects, those present at birth, are a product of improper development/formation of the chambers or valves of the heart. As a result, the healthy, developed portions of the heart have to increase work load to pump blood through the heart, which can in tum lead to heart failure. In addition, abnormal heart rhythms, or arrhythmias, can cause the heart to beat too quickly. This too creates extra work for the heart to pump blood correctly. A slow heart beat may prevent the myocardium from pushing enough blood out to the body; both scenarios cause a weakening of the myocardium and can lead to HF. Chronic conditions such as diabetes, anemia, hyperthyroidism, hypothyroidism, emphysema, lupus, or a build-up of iron, protein, or inflammatory cells can also contribute to heart failure. 20 Finally, acute heart failure can be brought on by viruses that attack the myocardium, severe infection, allergic reactions, blood clots in the lungs, and certain medications?O
CLASSIFICATION AND STAGING OF HEART FAILURE:
The New York Heart Association (NYHA) classification system is one of the oldest attempts to grade the severity of functional limitation among heart failure patients.
Initially developed in 1928, this classification scheme, although modified since its inception, has withstood the test oftime and is still widely used by physicians today; its accuracy, however, is widely debated. The scale is divided into four functional groups 
NYHA Class Symptoms I (Mild)
No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, or dyspnea.
II (Mild)
Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in fatigue, palpitation, or dyspnea.
III(Moderate)
Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes fatigue, palpitation, or dyspnea IV (Severe) Unable to carry out any physical activity without discomfort. Symptoms of cardiac insufficiency at rest. If any physical activity is undertaken, discomfort is increased.
Although widely respected, the guidelines to determine these classifications are subjective, with no set physical examination guidelines or standards; there are an endless number of physical exertion tests one can perform to come to the same conclusion.
Additionally, there are no set guidelines to distinguish different levels of ability, with terms like "slight" or "marked" leaving the interpretation of limited physical ability up to the physician. Common criteria used to determine NYHA class include: self-reported walking distance, difficulty climbing stairs, ability to walk to local landmarks, breathlessness interfering with daily activity, and breathlessness when walking around the house. 26 While some methods (such as walking distance) are more widely used than others not one distinct assessment has been accepted as superior to others, although the ACC has distinct parameters for classification; single clinics creating original classification schemes often protect their intellectual property from being used across mUltiple institutions. This inconsistency is apparent in the published literature, with 99% of research papers withholding a reference or description of their methods for assigning NYHA class in subjects. 26 However subjective the classitication system, the NYHA scheme is simple enough to provide a measure of the functional capability in heart failure patients and allow physicians to relay immediate feedback to these individuals. However one decides In contrast to the NYHA classification system, the ACC/ AHA developed classes (in addition to stages of disease) that correspond to levels of evidence on treatment protocol, and provide recommendation on the appropriate course of treatment to prescribe given the progression of heart disease. Class I describes a condition for which there is evidence and/or general agreement that the procedure or treatment is useful and effective;
Class II describes a condition for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment; Class IIa describes a condition in which the evidence or opinion is in favor of the procedure or treatment;
Class lIb describes a condition for which usefulness or efficacy less well established by evidence or opinion; and Class III describes conditions for which there is evidence and/or agreement that the procedure or treatment is not useful/effective and in some cases can be harmful. 14 The ACC/ AHA guidelines clearly lay out treatment recommendations based by stage, class, and level of evidence. Its advantage over In a randomized trial evaluating HF patients receiving ARBs or placebo throughout the course of study, combined end point mortality was lower among those receiving ARB (RR = 0.87; CI (0.77-0.97). Treatment with ARB also improved ejection fraction, NYHA class, and reported quality oflife. 7 The ELITE study, evaluating the effectiveness of ARBs in an elderly population of HF patients, showed a risk reduction of 32% among those using the medication relative to ACE-inhibitor use, primarily due to a decrease in all-cause mortality; hospitalization rates were less frequent among ARB users, as wel1. 24 ARB prescription is a common alternative to ACE-inhibitors due to their lack of adverse effects in patients. The ELITE-II study, in follow-up to the original study, aimed to determine if one course oftreatment was superior to the other (ACE-I vs. ARB).
In the population studied (not just the elderly, as in ELITE) while mortality and sudden death rates remained similar, the discontinuation of treatment in the ARB group due to adverse effects was significantly lower than in the ACE-I group (9.7 vs. 14.7, p<0.001).23
Overall, the study on efficacy of these two treatments has proven that either medication is beneficial in the pharmacotherapy of HF patients.
BETA-BLOCKERS:
Beta adrenergic receptor antagonists, commonly known as beta-blockers, are a class of drugs that block the effects of epinephrine on the beta receptors found in smooth muscle, airways, arteries, kidneys, and most importantly, the heart; beta-blockers reduce blood pressure by negating the effect of epinephrine, thereby reducing heart rate. Betablockers have proven effective in reducing overall mortality among HF patients, as well as improve LV function. 8 In a meta analysis of randomized trials involving patients with congestive heart failure, there was a greater than 30% reduction in odds of death among patients assigned a beta-blocker (CI 11-46%), representing an absolute reduction in mean annual mortality from 9.7-7.5%.8 Carvedilol, the most commonly prescribed betablocker, has been proven to effectively reduce mortality among patients with moderate to severe HF. In a random trial of HF patients (NYHA class III or IV) mortality was reduced by 35% among patients prescribed carvedilol, with an almost 25% reduction in combined mortality. 22 Beta-blockers usage among moderate HF patients showed an average death rate of 8% compared to 12.8% among non-users (OR=0.63, 95%CI 0.55-0.72); similar reductions were observed for hospital admissions for worsening HF, and composite outcome of death. 28 
SPIRONOLACTONE:
Spironolactone is commonly used in combination with other medications (such as those listed previously) to treat hypertension and HF. Although a relatively old medication, introduced clinically in 1959, its importance in HF management and treatment is often understated, as exhibited by a low level of evidence in ACC/ AHA guidelines for severe HF. In the RALE study of severe HF patients, a relative reduction of 30% was witnessed among those prescribed spironolactone as opposed to placebo (RR=0.70; 95% CI 0.60-0.82). This significant reduction was attributed to lower risk of death from progressive heart failure and sudden death from cardiac causes. Additionally, hospitalization rates were reduced by 35% and patients had a significant improvement in the symptoms of heart failure as assessed on the basis of their NYHA functional class. 25 Spironolactone added to ACE-inhibitors has been proven beneficial to improve heart dysfunction, as well. 3 Where the RALE study proved treatment was beneficial in patients with severe HF, data to support the beneficial effects in all HF patients remains inconclusive. Some research suggests an increase in adverse outcomes associated with spironolactone use when the RALE study guidelines for patient evaluation are not met. 5 DATA AND METHODS:
The data used in this thesis was derived from "Home HF care comparing patientdriven technology models", an AHRQ funded and IRB approved clinical study. This parallel, randomized, multi-site prospective cohort study assessed the impact of health hyperlipidemia, and diabetes mellitus all increase with increase in NYHA class. The comorbid conditions listed provide evidence of the deteriorating overall health of the patient, which may contribute to a decline in cardiovascular health; conversely, the deteriorating condition of the heart may provide a direct influence on any of these several conditions, most notably hypertension. One notable decline with an increase in NYHA class is ACC/ AHA compliance, with 76% compliance in the NYHA class II group, 56% in the class III group, and only 29% in the class IV group (which should be receiving the most careful treatment of all patients).
Overall rehospitalization rate within the study period was 59%, translating to 76 total patients; of these, 44 patients were re-hospitalized with a primary or secondary diagnosis for HF (secondary diagnosis was defined as any cardiovascular-related hospitalization). In the evaluation of guideline compliance for treatment therapies, 44.9% (22/49) of patients were rehospitalized for HF when ACC/AHA guidelines were NOT met, compared to 27.8% (22/79) among those patients in which guidelines for treatment were fulfilled. A risk reduction was exhibited among all individuals over the study period (1 year) when treatment guideline adherence was met. This decreased risk across the entire study period provides a baseline trend for the benefit of compliance, although variations exist at different time periods (listed in table 2).
To estimate the effect of time on risk of rehospitalization more precisely, relative risks were calculated for following time intervals: 0-14days, 15 days-l month (30 days), 31 days to 6 months (180days), and cumulative 30 day; cumulative risk was also calculated for the entire study period. Relative risks for age (2:65 years vs. younger than 65 years), race (white vs. non-white), and sex (male vs. female) were calculated for each time interval, as well as the relative risk for NYHA class (class IV vs. IIIIII) and ACC/ AHA compliance variables. Each relative risk calculated was controlled for study arm to account for treatment differences patients may have received, be it from a cardiologist, general practitioner, or nurse. The results are listed (along with 95% CI) in Table 2 : In addition, the argument for appropriate treatment was simplified for the purposes of analysis, using an all-or-none approach. In future studies, a stratification of partial adherence to guidelines could be used to indicate any weaknesses in a specific area of heart failure treatment, which extends beyond the scope of this research (ex.
Presence of hypokalemia and adverse interactions with spiranolactone). Of greater importance is the use of an intention-to-treat model in the original study, which assumes a patient complies with the recommended treatments; a study assessing medication intake at each rehospitalization event may provide a more accurate depiction of the hazard rates in these heart failure patients, setting apart those that follow prescribed treatment with those that do not.
Given the overall mortality rate among heart failure patients, the results from the regression analysis should be assessed on the basis of their clinical implications, considering the relative risks and survival effects among the patients enrolled. The small sample size (n=128) did not achieve statistical significance for more complex models including variables such as comorbid conditions, as stratification often lead to small subcategories. Because of this, a simplified model was created to account for the lack of power. The effect size (decreased hazard among those in which treatment guidelines were adhered) solely due to treatment is a large estimate which should be considered of clinically meaningful importance, due to an already increased risk of failure in the target population. The confidence interval in the overall model, suggest a positive effect in this patient population. Given that the study population was a representation of a diverse group of heart failure patients, the effect size oftreatment can be extrapolated to the larger population of heart failure patients. Effect size within the immediate time after enrollment into the study suggests that compliance with the set ACC! AHA guidelines from the outset of heart failure would improve immediate rehospitalization rates, which has both a workload benefit as well as a monetary benefit to the medical institutions receiving these patients. Additionally, since heart failure treatment is one of the largest expenditures in healthcare, even a small reduction in overall mortality would benefit our healthcare system on a large scale.
DISCUSSION:
Previous studies looking at the relationship between treatment and rehospitalization rates among heart failure patients have concluded similar results, arguing that appropriate treatment reduces the rates in which a patient is readmitted; the implication, although intuitive, is often understated based on the cumulative risk among these patients. What makes this analysis unique is that importance of appropriate treatment has been assessed not only on a larger time scale (1 year This program, which is expected to generate significant savings in the Congressional Budget, is designed to align payment with outcomes, driving meaningful reductions in all-cause readmissions. The measure proposed is a hospital-specific, risk-standardized 30 day readmission ratio which follows index admissions for acute myocardial infarction (AMI) and HF. As a result, underperforming hospitals will incur a reduction of 1 % or less in Medicare reimbursements for inpatient services; payment penalties can increase to 2-3%, based on the higher readmission rates. This would translate into an average cost per hospital of$125,000.4 Hospital readmission rates, based on 2010 data would have placed half of all eligible hospitals at risk of penalties regardless of geography, bed size, or teaching status.
The issue of proper treatment and penalty for readmission is one that has to be weighed from the sides of the physicians and clinicians, and not that of the agencies working to reduce rehospitalization rates. A couple of issues to contemplate with the proposed hospital readmissions reduction program include higher readmissions rates among hospitals serving low-income individuals, and hospitals keeping very ill patients having higher readmissions/lower mortality. In addition, heart failure mortality may not be the direct cause of readmission; any number of maladies or physical problems can arise sending someone back to the hospital. The 20% reduction goal placed by CMS is based on the average rate of rehospitalization among Medicare recipients within the first month after hospital discharge for any purpose; however, readmission for only a limited number of conditions (HF included) would be recorded when assessing penalties accrued.
From this study, it is clear that age, HF class, and especially treatment guideline adherence is an important determinant in the first 30 days; this is exhibited by an increase in relative risk among age and NYHA class, and a decrease with treatment compliance (listed previously in Table 2) In conclusion, from this analysis we have assessed the economic and clinical benefits of appropriate treatment for heart failure patients. Looking at various factors that influence the overall rehospitalization rates including the severity of heart failure, treatment compliance is arguably the most important variable within the results generated. While the sample of patients was small in this study, the large effect -exemplified by hazard rates among those receiving appropriate treatment -argues the clinical importance of adhering to the ACC/ AHA guidelines, while controlling for several other factors that contribute to increased risk. Further studies with a larger sample size would be needed to reaffirm the finding from this analysis with a strong statistical significance. With the initiation of the Affordable Care Act, however, there is even more of an incentive for hospitals to become thorough in their efforts to properly treat these high risk patients, and the results from our study reaffirm this point.
